New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
07:06 EDTFATEFate Therapeutics announces issuance of U.S. patent for Stem Cell Cultures
Fate Therapeutics announced that the U.S. Patent and Trademark Office has issued Patent No. 8,691,573 entitled "Stem Cell Cultures." The newly issued patent claims a class of small molecule inhibitors of Rho-associated kinase, or ROCK, that are crucial to the therapeutic application of human induced pluripotent stem cells, or hiPSCs. Modulators belonging to the patented class have been shown to be necessary for the high-throughput derivation of transgene-free hiPSCs, and for the maintenance, survival and genomic stability of hiPSCs in culture. Fate Therapeutics holds an exclusive license from The Scripps Research Institute to the patent in all commercial fields.
News For FATE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
06:18 EDTFATEFate Therapeutics 6M share Secondary priced at $5.00
Leerink and BMO Capital acted as joint book running managers for the offering.
May 18, 2015
16:10 EDTFATEFate Therapeutics files to sell 6M shares of common stock
Fate Therapeutics intends to use the net proceeds from the offering for clinical development and research activities, working capital and other general corporate purposes. Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Wedbush PacGrow and H.C. Wainwright & Co., LLC are acting as co-managers

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use